Church + Dwight Co Inc CHD

Thesis

Church & Dwight Co Inc (CHD) is a 180-year-old US consumer-staples compounder built around two pillars: a value/premium dual-brand laundry-and-cleaning franchise anchored by ARM & HAMMER and OXICLEAN, and a string of bolt-on power brands (HERO acne, TheraBreath, BATISTE, WATERPIK, Zicam, Touchland) bought into fast-growing personal-care niches at multiples low enough to compound. The 12-step scorecard registers this quality cleanly: composite 74/100, profitability 18/25, capital allocation 20/25, balance sheet 15/20, valuation 21/30. Ten-year average ROIC of 13.5% and 5-year FCF/Net-income conversion of 1.33 confirm the engine: brands with pricing power throwing off more cash than reported earnings, while net debt to EBITDA of 1.64x and interest coverage of 8.55x leave room for the next bolt-on. Share count has barely moved (down 0.66% over a decade) — buybacks neutralize dilution rather than juice EPS, and the dividend has compounded for 124 consecutive years. The catch is the same catch every staples compounder presents: at $96.02, the stock trades at 41.2x TTM earnings versus a 31.1x ten-year average and at 22.3x EV/FCF, with a reverse-DCF implied growth rate of 8.1% that is well above the ~3-4% category top-line CHD is actually delivering ex-acquisitions. The scorer's IV range is $89.82 (low) / $136.84 (base) / $165.39 (high). At today's price, P/IV is 0.70 — meaning we are at the low end of fair, not at a discount. The price/IV math: pay $96 to maybe own $137 of base-case value, with the floor sitting essentially at the current price. That is a Hold — the franchise is compoundable, but I want $89 or lower before sizing up.

Moat

Church & Dwight's moat is best understood as a bundle of small, narrow moats held together by retail-shelf logistics and a value-bias positioning. Apply Buffett's brand-and-shelf framework [4] ("buy commodities, sell brands" — the formula behind Coca-Cola and Wrigley) and Damodaran's brand-management framing [1] (Coca-Cola's value flows from "relentless focus on making its brand name more valuable globally"): CHD owns a dozen brand-led mini-monopolies in fragmented categories where being #1 or #2 with shelf gravity at Walmart, Target, and Costco is the core economic asset.

1. Intangibles / brand power — STRONGEST. ARM & HAMMER baking soda has been on US shelves since 1846 and is essentially synonymous with sodium bicarbonate consumer applications (laundry, dental, cat-litter deodorizing, cleaning, refrigerator boxes). TROJAN is the #1 condom brand in the US, WATERPIK is #1 in water flossers, FIRST RESPONSE is #2 in pregnancy tests, and HERO Mighty Patch is the dominant pimple-patch brand in a category HERO essentially created. Seven "power brands" — ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, HERO and TOUCHLAND — represent ~70% of net sales and profits. These are the kind of mid-sized brand assets that pass Damodaran's test [1]: cash flow is the consequence of brand strength, not the cause. The 10-year average ROIC of 13.5% is the financial signature of intangibles doing real work.

2. Cost advantages — NARROW but real, only in laundry. ARM & HAMMER laundry's wedge is value pricing: a deliberate sub-Tide positioning that gives CHD pricing room to take share during recessions when consumers trade down. The dual-brand ARM & HAMMER (value) / OXICLEAN (premium add-on) structure inside laundry creates a price-laddering moat against Procter & Gamble's Tide. CHD has historically been the lowest-cost major laundry detergent producer in the US thanks to the captive baking-soda input. Outside laundry, scale economics are modest — these are bolt-on brands where CHD provides distribution and marketing leverage rather than manufacturing cost advantage.

3. Distribution / shelf real estate — NARROW. The shared moat across the portfolio is that CHD is large enough (~$6B revenue) to be a top-20 vendor at Walmart, Target, Amazon, and Costco, but small enough to still earn category-captain status in niches the giants ignore (oral rinse, dry shampoo, gummy vitamins until divested, hand sanitizer, acne patches). Shelf gravity compounds: once Mighty Patch wins the category at Target, a competitor must out-spend CHD's marketing dollar to evict it.

4. Switching costs — NONE. Consumer staples have ~$0 switching cost in the literal sense (try the other brand next time at the shelf). Stickiness comes purely from habit and brand recall, not lock-in [3].

5. Network effects — NONE. Not applicable.

Competitor stress test ($10B + 5 years): Procter & Gamble, Unilever, Colgate-Palmolive, Reckitt, Henkel, and Kenvue all dwarf CHD. P&G could outspend CHD 5:1 on any single brand. So why doesn't it? Because in CHD's specific niches (baking-soda laundry, pimple patches, dry shampoo, water flossers) the addressable market is too small to move the needle for P&G — the same dynamic that protects See's Candies [2]. CHD's moat is that its categories aren't worth fighting over, and within them brand-recall and shelf-position are entrenched.

Erosion risks are real and getting worse: (a) private-label penetration is rising in laundry — Costco's Kirkland and Walmart's Great Value are credible substitutes for ARM & HAMMER value tiers; (b) WATERPIK is already showing erosion — the 10-K discloses fair value at only 117% of carrying value (down from 135% in 2024), with management citing distribution losses and consumers "choosing value brands amid inflation"; (c) Spinbrush was exited in 2025 at a $21.2M pre-tax loss and Flawless and Waterpik showerheads were also wound down (~$118M of annual sales); (d) the VitaFusion / L'il Critters gummy-vitamin business — once a power brand — was sold to Piping Rock on December 31, 2025 after losing share. So three of the eight prior "power brands" have either been exited or divested in twelve months. That is not a wide-moat profile; it is a portfolio undergoing real natural selection.

Moat verdict: NARROW.

Management & Capital Allocation

CHD's management story is the capital-allocation playbook: predictable category growth funded by laundry-and-cleaning, recycled into bolt-on personal-care brands at sensible multiples, with disciplined buybacks and a 124-year dividend streak. The five capital-allocation choices, scored:

1. Reinvest in the existing business — A-. Capex is ~3% of sales; maintenance capex is uncertain enough that the scorer flagged a >50% spread ("Maintenance capex uncertain; widen IV range"). FCF conversion of 1.33x net income over five years is excellent and tells you the reinvestment burden is genuinely light — the brand engine throws off more cash than reported earnings.

2. Acquire — B+. The track record is genuinely good for a staples roll-up. Hero Cosmetics (acne patches, 2022) is the standout: bought for $630M and inside three years became one of CHD's seven power brands. TheraBreath (oral rinse, 2022) and Zicam (cold remedies) similarly added growth-rate to a 3-4% organic-growth core. Touchland was acquired on July 16, 2025 for $656M plus a $159M earn-out plus $50M of equity to the founder over two years (~$865M all-in for a brand doing ~$115M in 2024 sales — roughly 7.5x trailing sales for a category-leader hand-sanitizer brand growing fast). That price tag is rich; the model is that Touchland follows the Hero playbook of triple-digit growth post-acquisition. The discipline grade reflects two failures (Spinbrush exit at a $21.2M pre-tax loss, Flawless impairment, VitaFusion divested) which proves portfolio pruning rather than reckless capital deployment, but also reveals that 25-30% of the prior power-brand list didn't compound. Net: better than industry average but not Berkshire-class.

3. Debt — A. Net debt/EBITDA at 1.64x is conservative for a staples company; interest coverage 8.55x leaves room. CHD has historically delevered to <1.5x within 24 months of major deals. The Touchland deal was funded with cash on hand, which is how a discipline-driven CFO funds a $865M deal in a high-rate environment.

4. Buybacks — C+. Share count is down only 0.66% over ten years. CHD runs an "evergreen" repurchase program (authorized 2014) that explicitly targets dilution-offset rather than EPS-juicing. That is philosophically the right model — Buffett would approve of not buying back overpriced stock — but at 41x TTM earnings the management team is correctly not leaning into buybacks, which means buybacks won't add value at today's price. Average historical P/IV at the time of repurchase has been mediocre, not great.

5. Dividends — A. 124 consecutive years of dividend payments and 29 consecutive annual increases. The dividend is sacred and the payout ratio (~35-40% of FCF) leaves room.

Communication quality — B+. The 2025 10-K was unusually candid: explicit disclosure of the WATERPIK trade-name fair value compression (135% → 117% headroom), explicit pre-tax loss recognition on Spinbrush ($21.2M), explicit divestiture rationale on VMS. PSU compensation now uses a balanced TSR (vs. peer group) + cumulative cash-flow-from-operations metric, which is shareholder-aligned. CEO Matthew Farrell (since 2016) communicates clearly about the "evergreen" 3% organic / 8% EPS / 4-quartile TSR algorithm that the company is unable to reliably hit anymore — current organic growth is below trend and 2026 guidance reflects that.

The one yellow flag: Touchland's $865M all-in price implies ~7.5x trailing sales, and the 25% EBITA-margin assumption used for Waterpik's impairment test looks aggressive given the disclosed distribution losses. Management is willing to pay full price for growth, which is fine when it works (Hero) but punishing when it doesn't (Flawless, VMS, Spinbrush).

Capital allocator: B.

Industry Structure

Church & Dwight competes in three loosely-related industry structures: (a) US household cleaning and laundry, (b) US personal care (oral, hair, skin, sexual health), and (c) niche specialty consumer (cold remedies, hand sanitizers, pet care). Porter's Five Forces, weighted by profit pool:

1. Rivalry — HIGH. Procter & Gamble, Unilever, Colgate-Palmolive, Reckitt, Henkel, Kenvue, and Energizer compete in CHD's core categories. In laundry, Tide alone is roughly 4-5x ARM & HAMMER's share. Rivalry is intensified by the fact that retailers (Walmart, Target, Amazon, Costco) treat staples categories as traffic drivers and pressure all manufacturers on price simultaneously. CHD survives by occupying "value" positioning that P&G cannot crash without cannibalizing its premium tiers — a structural truce, not absence of rivalry.

2. Threat of new entrants — MEDIUM-HIGH and rising. The Hero Cosmetics story is itself the proof: a DTC brand built on Amazon and TikTok created a $100M+ category (acne patches) in five years, then sold itself to CHD for $630M. Touchland is the same template (DTC hand-sanitizer brand, viral TikTok marketing, acquired by CHD for ~$865M). What CHD has been buying is the very disruption that threatens its incumbents — but the inverse is also true: the next Hero / Touchland may not sell to CHD, and DTC entrants now have credible paths to scale via Amazon and Shopify without relying on CHD's distribution moat.

3. Threat of substitutes — MEDIUM and rising. Private label is the persistent substitute, and 2024-2025 inflation has measurably accelerated trade-down. The 10-K explicitly attributes WATERPIK's troubles to consumers "choosing value brands amid inflation." Consumers are also substituting between behavioral routines (e.g., dry-shampoo vs. extra wash, water-flosser vs. string floss vs. nothing) which is a slower but ongoing erosion vector.

4. Bargaining power of buyers — VERY HIGH. Walmart alone is ~20%+ of CHD's revenue. Amazon is the fastest-growing channel and uses CHD's pricing data to pressure margin. Retailer buyers have category-management power: they decide shelf facings, slotting, end-cap promotion, and increasingly own the data on velocity. The CPG industry has been losing 50-100 bps of gross margin per decade to retailer power, and CHD is not exempt.

5. Bargaining power of suppliers — LOW-MEDIUM. Sodium bicarbonate, surfactants, plastic packaging, and corrugate are commoditized inputs; CHD is vertically integrated in baking soda which is a real cost-advantage moat. Tariffs are a 2025-2026 risk explicitly flagged in the 10-K ("impact of tariffs" and "increased trade restrictions"), which raises supplier-side costs but affects all peers symmetrically.

Value pool location and trajectory: The traditional staples profit pool (laundry, cleaning, oral care) is shrinking modestly in real terms — total US category growth is roughly population + 1-2%, and private-label is taking ~50 bps annually. The growth profit pool is shifting to (a) skincare-adjacent personal care (Hero), (b) on-trend TikTok-native brands (Touchland), and (c) better-for-you niche segments (TheraBreath). CHD has been smart enough to redeploy into those pools, but it pays acquisition multiples that capture most of the future value to the seller.

A Buffett-style filter [2]: This is closer to a See's-style "unexciting industry" than a Coca-Cola-style monopoly. Per-capita laundry consumption is flat and barely grows; personal-care niches grow faster but are eaten by entrants as fast as they are minted. The five-force structure is workable but not great — it produces 13.5% ROIC, not 30%.

Industry Verdict: Average.

Inversion (Bear Case)

I am now a short-seller. I am going to break this thesis.

1) The single event that kills this. A WATERPIK impairment charge of $300-500M in 2026 or 2027. The 10-K explicitly states the trade name's fair value is at 117% of $644.7M carrying value, down from 135% one year earlier. That cushion shrank by 18 percentage points in a single year. One more year of distribution losses (already disclosed) plus tariff cost pressure (already disclosed) plus continued trade-down to value brands (already disclosed) and the cushion goes negative. CHD will be forced to recognize a non-cash impairment charge of hundreds of millions, which destroys the "power-brand" narrative and forces the multiple to recompress. Compound that with a similar trajectory on TheraBreath (which faces increasing private-label oral-rinse competition at Walmart and Target) and you have a 2026-2027 narrative-breaking event for a stock priced for 8.1% implied growth.

2) Why the moat is narrower than bulls think. Three of CHD's prior eight "power brands" — Spinbrush, Flawless and VitaFusion — were exited or divested in one year (2025). That is a 37.5% mortality rate on the company's own designated franchise list. Bulls cite ARM & HAMMER's 180-year history; the bear cites Spinbrush's death certificate. The truth is that CHD owns one durable franchise (ARM & HAMMER baking-soda extensions) and a rotating cast of 8-10 mid-sized brands that compete in categories where DTC entrants now scale on TikTok in 24 months. Buffett's See's Candies test [2] requires a stable industry where rivals come and go without disturbing the moat. CHD operates in categories where the category itself mutates every five years (gummy vitamins were a darling in 2018, dead in 2025; pimple patches exist now, may be dead by 2030). That is not the See's Candies profile.

3) Why management is worse than it appears. Look at the M&A track record without survivorship bias. Bulls cite Hero ($630M, working great) and TheraBreath (working). The bear cites: Flawless (impaired), Spinbrush (impaired and exited), VMS / VitaFusion (bought via Avid Health for $650M in 2012, sold to Piping Rock for an undisclosed but reportedly far smaller number in 2025), and the WATERPIK acquisition itself (paid $1.0B in 2017, now showing material trade-name impairment risk). Touchland was acquired in 2025 at ~7.5x trailing sales — a multiple that requires Hero-tier compounding to justify. The base rate on staples roll-up acquisitions at >5x sales is bad. Management's confidence is calibrated to its successes, not its full distribution. The PSU comp tied to TSR + cumulative CFO is short-cycle (3-year), which incentivizes deal velocity over discipline.

4) What bulls are extrapolating that won't hold. Bulls extrapolate three things: (a) 3-4% category organic growth — but actual 2024-2025 organic growth has been below this, and the most recent quarterly cadence is 1-2%; (b) gross-margin expansion from cost-savings programs — but tariff and labor inflation are running ahead of cost-take; (c) the M&A flywheel — but acquisition multiples for branded DTC growth assets have re-rated up by 50-100% in the last five years, structurally compressing future ROIIC. The reverse-DCF implies 8.1% growth. CHD has not delivered 8.1% organic growth in a single year since 2018; everything above 3-4% has been M&A. To justify the current $96 price, CHD has to deploy $1B+ per year at Hero-tier IRRs for a decade. The base rate on that is approximately zero.

5) Valuation trap (multiple compression / regime change). CHD trades at 41.2x TTM earnings versus a 31.1x ten-year average — a 33% premium to its own historical mean. The 10-year average occurred during a zero-interest-rate environment that is over. Mean reversion alone takes the stock to ~$72 (96 × 31.05/41.22 = $72.3). EV/FCF at 22.3x is similarly elevated for a low-growth staples name. The peer group (PG ~28x, CL ~26x, KMB ~17x, RKT ~21x in GBP) suggests CHD is the priciest large staples name, and CHD's organic-growth profile is not measurably better than P&G or Colgate. Multiple compression to 25x earnings on flat EPS is a 39% drawdown to ~$58. Layer in a $300M WATERPIK impairment that knocks reported earnings down for a year and forces the multiple to compress against headline numbers, and you have a downside scenario in the $55-70 range — well below the scorer's $89.82 IV-low (the IV-low does not assume regime change).

If I am right, the stock could be worth $60-70 within 24-36 months.

Lollapalooza Bias Check

Biases active in me as the analyst right now:

Authority bias — STRONG. CHD has a 124-year dividend streak, a 180-year corporate history, and is a default "high-quality compounder" name in every staples-investor presentation. I came in primed to write a Buy, and I had to consciously unwind that to get to Hold. The composite score of 74 reinforces the priming — it's a high score, and I anchored to it. Counterweight: 74/100 is good but not exceptional, and 21/30 on valuation is the weakest sub-score. The valuation score is what should drive the action, and it argues against the authority-bias conclusion.

Anchoring — MODERATE. I am anchoring to the 31.1x 10-year average P/E as if that is the "normal" multiple. But the 10-year average was set during ZIRP. A more honest comparison is the 2002-2008 average (likely closer to 22-24x) which would imply meaningful downside even from base IV. The IV math from the scorer treats 31.1x as a fair anchor, and I am inheriting that anchor.

Confirmation bias — MODERATE, in the opposite direction once I went bearish. Once I started writing the inversion, I started cherry-picking the Spinbrush, Flawless, VitaFusion, and WATERPIK impairment items to support a bearish narrative. The Hero acquisition is genuinely working. TheraBreath is genuinely growing. Touchland may compound — I don't actually know yet. I need to discount my inversion intensity by ~20%, which is roughly what the Hold rather than Sell recommendation reflects.

Recency bias — MODERATE. The 2025 portfolio pruning is fresh in my mind. Three brand exits in one year feels alarming, but it may be exactly the kind of disciplined portfolio surgery a healthy management team should do. The opposite framing — "CHD pruned $118M of low-growth revenue to focus on power brands" — is also true. Recency bias is making the pruning feel like decay rather than discipline.

Social-proof bias — WEAK. I haven't checked sell-side consensus or hedge-fund holdings, so this is dormant. If I had, I would probably anchor to a Buy rating since CHD is widely held by quality-compounder funds.

Deprival super-reaction — WEAK but present. The price was $115 a year ago. "Buying at $96" feels like buying the dip. That feeling is unrelated to IV. The real question is the relationship of $96 to the $89.82 IV-low, not to the 52-week high.

Net effect: my biases were pulling me toward Buy at the start, then toward Sell during inversion. The actual answer — Hold with a target buy at IV-low ($89) — is the bias-corrected position.

10-Year Outlook

Same fundamental business model in 10 years? Mostly yes. CHD will still be a US-led consumer-staples manufacturer running 8-12 power brands across laundry, cleaning, oral care, skin care, sexual wellness, and niche specialty. ARM & HAMMER will still exist as the franchise core. The bolt-on M&A flywheel will continue. So far so Munger-friendly.

Larger customer base? Modestly. US population grows ~0.5% annually. International expansion (currently ~17% of sales) is a structural opportunity but progress has been slow for a decade. International scale-up of TheraBreath / Hero / Touchland could push international to 25% of sales by 2035, which is a real but limited tailwind.

Higher profit per customer? Probably yes via mix shift to premium personal-care brands (Hero gross margin > ARM & HAMMER laundry gross margin), partially offset by retailer pricing pressure and tariffs. Net: maybe 100-200 bps of operating-margin expansion over a decade, not a dramatic re-rate.

Wider moat? Probably narrower, not wider. Private-label competence is improving (Costco Kirkland is now genuinely good), DTC entrants compress the on-shelf advantage, and TikTok shortens brand life-cycles. The moat is durable but mathematically shrinking around the edges. WATERPIK's fair-value compression from 135% to 117% in one year is the canary.

Single biggest threat? Two-front compression: (a) retailer-power and private-label trade-down on the value end, and (b) DTC and TikTok-native brand acceleration on the premium end. CHD's middle-market positioning gets squeezed from both sides, with M&A as the only release valve — but M&A multiples are now structurally elevated.

Confidence call. Will CHD still be a real company, throwing off cash, paying a dividend, in 2036? Almost certainly yes. Will it have meaningfully compounded per-share value at a rate that justifies paying $96 for it today? That is genuinely uncertain — depends on M&A discipline, WATERPIK trajectory, and tariff path. The qualitative case is sound; the price case is not. I am at medium confidence in the long-term franchise, low confidence in the price.

CONFIDENCE: medium